文献速递心外重症与机械循环支持

HeartMate 3 左心室辅助装置支持患者五年结局:单中心经验

Five-year outcomes of patients supported with HeartMate 3: a single-centre experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该前瞻性队列研究纳入2014年参与HeartMate 3 CE标记临床试验的8例患者,随访5年,主要终点为5年生存率。结果显示5年生存率100%,无右心衰竭、溶血、泵血栓、泵故障或神经系统事件,传动系统感染发生率为0.25次/患者年,生活质量和NYHA心功能分级显著改善。

要点

  • HeartMate 3支持患者5年生存率达100%,无泵血栓和溶血事件。
  • 传动系统感染发生率为0.25次/患者年,为主要不良事件。
  • 生活质量和NYHA心功能分级在植入后及整个随访期显著改善。

核心结论

  • HeartMate 3在5年随访中表现出优异的血液相容性,生存率高且并发症发生率低。

研究设计与样本

  • 前瞻性队列研究,纳入2014年参与HeartMate 3 CE标记临床试验的8例患者,每3个月随访一次,所有患者完成5年随访。

主要发现

  • 5年生存率为100%,患者中位支持时间为1825天(最短-最长:101-1825天)。
  • 2例患者成功接受心脏移植。
  • 无右心衰竭、溶血、泵血栓、泵故障或神经系统事件发生。
  • 6例患者发生传动系统感染,发生率为0.25次/患者年。
  • 与基线相比,生活质量及NYHA心功能分级在植入后及整个随访期显著改善;3年后肾功能和6分钟步行试验结果略有下降。

临床怎么用

  • HeartMate 3可作为长期左心室辅助支持选择,5年内血液相容性良好且生存率高,但需关注传动系统感染及远期肾功能和运动能力变化。

局限性

  • 单中心经验,样本量仅8例,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The HeartMate 3 left ventricular assist device was first implanted in 2014 and received the Conformité Européenne mark in 2015. Since then, several trials demonstrated its high haemocompatibility associated with good survival and low adverse events rates. Herein, we report our institutional experience with patients supported with HeartMate 3 for 5 years. METHODS: This prospective cohort study included patients receiving a HeartMate 3 implantation in 2014 as part of the HeartMate 3 Conformité Européenne Mark clinical trial. Patients had follow-up visits every 3 months while on left ventricular assist device support, and all patients completed the 5-year follow-up. The primary end point was survival at 5 years. Secondary end points included adverse events, health status and quality of life. RESULTS: Eight patients (men: 75%) aged 59 years (min-max: 52-66 years) were enrolled. At 5 years, survival was 100%. Patients remained on support for a median time of 1825 days (min-max: 101-1825 days); 2 patients successfully received cardiac transplants. No right heart failure, haemolysis, pump thrombosis, pump malfunction or neurological events occurred in any patients. A driveline infection was observed in 6 patients (0.25 events/patient-year). Compared to baseline, a significant improvement in quality of life and in New York Heart Association functional class was noted after the implant and for the whole follow-up time. A slight decline in kidney function and in the 6-min walk test results occurred after 3 years. CONCLUSIONS: This study reports the longest single-centre follow-up of the HeartMate 3, showing excellent haemocompatibility over time with high survival and low complication rates at 5 years.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Schmitto JD, Mariani S, Li T, et al. Five-year outcomes of patients supported with HeartMate 3: a single-centre experience. Eur J Cardiothorac Surg. 2021. PMID: 33585913. doi:10.1093/ejcts/ezab018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。